Resonant technology can dramatically expand your drug discovery pipeline. Resonant customizes tumor microenvironment models to reflect specific disease states and microenvironment conditions.
Resonant has a large number of discovered and validated therapeutic candidates, ready to be launched into your preclinical development program. This catalog contains targets validated for anti-tumor functionality, antibody-drug conjugate development, and which have been computationally ranked for therapeutic index potential.
Our platform technology and pipeline processes is highly customizable, enabling further modeling of specific cancer, fibrosis or inflammation models of interest. We utilize high-dimensional analyses to select the best cancer models for each new application, maximizing the potential benefit of each new run. Partner with Resonant to maximize on your strategic insights and to develop multiple new lead candidates in as little as 12 months.
Every therapeutic developed by Resonant is rigorously evaluated by cutting edge biological techniques combined with computational insights. We further prioritize candidates based on predicted therapeutic index, applicability across a wide variety of cancers, and by algorithmic assessment of the intellectual property position.